14-day Premium Trial Subscription Sign Up For FreeGet Free

Weaker Stock
Today CLVS ranks #17586 as sell candidate. Get a Free Stock at Robinhood
Stronger Stock

Clovis Oncology Stock Forecast NASDAQ:CLVS

$2.76 (-11.25%)

Volume: 5M

Closed: Dec 03, 2021

Hollow Logo Score: -8.428

Clovis Oncology Stock Forecast

$2.76 (-11.25%)

Volume: 5M

Closed: Dec 03, 2021

Score Hollow Logo -8.428
Which way will CLVS go? Request
Key Stats
P/E Ratio -1.20
Beta 1.35
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] The Clovis Oncology stock currently holds an RSI14 at 22 and is oversold on RSI14. The stock being oversold is no guarantee for instant reaction up as some stocks may be oversold for a long time. It is important to review the previous RSI-history to get an indication of the RSI-sensitiveness.

Volatile ride for Clovis Oncology stock price on Friday moving between $2.75 and $3.11
(Updated on Dec 03, 2021)


Sell candidate since 2021-11-05 Loss -37.56%

The Clovis Oncology stock price fell by -11.25% on the last day (Friday, 3rd Dec 2021) from $3.11 to $2.76. During the day the stock fluctuated 13.09% from a day low at $2.75 to a day high of $3.11. The price has fallen in 6 of the last 10 days and is down by -20.92% for this period. Volume has increased on the last day by 288 thousand shares but on falling prices. This may be an early warning and the risk will be increased slightly over the next couple of days. In total, 5 million shares were bought and sold for approximately $14.85 million.

The stock has broken the wide and falling short-term trend down. Firstly a stronger fallrate is indicated, but false breaks and "sell-off" may occur. However, a further fall is realistic and any reactions back to the breaking point ($3.44) are considered to be a "second chance" to get out. According to the fan-theory $2.59 will represent the new bottom line of the next trend, but it is far too early to say this for certain.

Signals & Forecast

There are few to no technical positive signals at the moment. The Clovis Oncology stock holds sell signals from both short and long-term moving averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $3.09 and $3.92. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Tuesday, November 02, 2021, and so far it has fallen -42.02%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume rose on falling prices yesterday. This may be an early warning and the stock should be followed more closely.

Support, Risk & Stop-loss

There is no support from accumulated volume below today's level and given the right condition the stock may perform very badly in the next couple of days.

This stock may move very much during the day (volatility) and with a very large prediction interval from the Bollinger Band this stock is considered to be "very high risk". During the last day, the stock moved $0.36 between high and low, or 13.09%. For the last week, the stock has had a daily average volatility of 8.65%.

Clovis Oncology is oversold on RSI14 (22). Some stocks may drop long and hard while being oversold on RSI before turning, which increases the general risk.

Our recommended stop-loss: We hold an negative evaluation for this stock. No stop-loss is set.

Is Clovis Oncology stock A Buy?

Clovis Oncology holds several negative signals and is within a wide and falling trend, so we believe it will still perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Due to some small weaknesses in the technical picture we have downgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Strong Sell candidate.

Current score: -8.428

Predicted Opening Price for Clovis Oncology of Monday, December 6, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price December 6, 2021 Current price
$2.87 $2.76 (Undervalued)
Strong Sell Candidate Downgraded

Remember To Visit Our YouTube Channel

Analyst Ratings

On Nov 15, 2021 "SVB Leerink" gave "$3.00" rating for CLVS. The price target was set to $3.94.

Volatility and Risk
Daily Average Volatility: 8.65 %
Overall Risk: Very High High Medium Low Very Low
Volatility
8.65 %
Daily Average Volatility
Overall Risk

Very High
High
Medium
Low
Very Low

Support & Resistance

Resistance: $2.94
Price: $2.76
No Support Found

CLVS Insider Trading Show all Trades

INSIDER POWER

0.686

Last 100 transactions
Buy: 76 967 | Sell: 112 266 (Shares)
Date Action Amount Person Type
Dec 02, 2021 Sell 562 Gross Paul Edward Restricted Stock Units
Dec 02, 2021 Sell 248 Gross Paul Edward Common Stock
Dec 02, 2021 Sell 687 Ivers-read Gillian C Restricted Stock Units
Dec 02, 2021 Sell 304 Ivers-read Gillian C Common Stock
Dec 02, 2021 Sell 18 Harding Thomas C. Restricted Stock Units
Show all Insider Trades
INSIDER POWER

0.686

Last 100 transactions
Buy: 76 967 | Sell: 112 266 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 3.23 17.15 %
3.10 12.17 %
3.01 9.09 %
Current price: 2.76
Support 2.74 -0.88 %
2.65 -3.95 %
2.51 -8.94 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 3.27 18.48 %
3.12 13.04 %
2.94 6.52 %
Current price 2.76
Support 0 .
0 .
0 .

Click to get the best stock tips daily for free!

About Clovis Oncology

Clovis Oncology Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. It is developing three product candidates, which include Rociletinib, an oral epidermal growth factor receptor and mutant-selective covalent inhibitor that is under review with the U.S. and E.U. regulatory authorities for the treatment of non-small cell lung cancer; Rucapar... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT